Wendy B. Young - 17 Sep 2026 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Director
Issuer ticker: ADIL
Reported as of: 17 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Sep 2026, 19:25:34 UTC
Prior SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Davidson, Attorney-in-Fact

Key filing fact

Wendy B. Young filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 21 Sep 2026.

Key facts

This page summarizes Wendy B. Young's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Sep 2026, 19:25.

Change

Previous filing in this sequence was filed on 16 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002042847 Primary reporting owner

Young Wendy B.

Relationship: Director
Address: C/O ADIAL PHARMACEUTICALS, INC., 4870 SADLER ROAD, SUITE 300, GLEN ALLEN
Signature: /s/ Matthew Davidson, Attorney-in-Fact
Signature date: 21 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +25,666
Change %
Price: $0.000000^*
Shares after: 25,666
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,666
Exercise price: $2.98
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 ("Stockholder Approval Date").

Footnote F2

2,138 shares subject to the stock option vested on the Stockholder Approval Date and the remaining 23,528 shares subject to the stock option shall vest in substantially equal installments over a 33-month period, beginning on October 12, 2026.